Open AccessPhase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Author(s) -
Guillermo GarciaManero,
Steven D. Gore,
Christopher R. Cogle,
Renee Ward,
Tao Shi,
Kyle J. MacBeth,
Eric Laille,
Heidi Giordano,
Sarah Sakoian,
Elias Jabbour,
Hagop M. Kantarjian,
Barry Skikne
Publication year - 2011
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2010.34.4226
Subject(s) - azacitidine , medicine , myelodysplastic syndromes , chronic myelomonocytic leukemia , nausea , tolerability , gastroenterology , adverse effect , pharmacodynamics , neutropenia , myeloid leukemia , pharmacokinetics , hypomethylating agent , febrile neutropenia , leukemia , myeloid , pharmacology , toxicity , bone marrow , dna methylation , gene , gene expression , chemistry , biochemistry
To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom